SutroVax is a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
SutroVax is seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
SutroVax was founded in 2013 by Grant Pickering and Jeff Fairman. The company is headquartered in Foster City, California.
SutroVax’s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae.
SutroVax's cell-free protein synthesis platform, comprising the XpressCFTM platform and its proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the company believes conventional vaccine technologies currently cannot.
SutroVax’s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales.
SutroVax is backed by TPG Growth, RA Capital Management, Janus Henderson Investors, Abingworth, Longitude Capital, Frazier Health Care Partners and others. The company raised $110M in a Series D round on Mar 26, 2020. This brings SutroVax's total funding to $281M to date.